Cas:64626-32-0 7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid manufacturer & supplier

Chemical Name:7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid

CAS.NO:64626-32-0

Synonyms:(9β,13E,15S)-9,11,15-Trihydroxythrombox-13-en-1-oic acid;D-erythro-Pentopyranose, 4-(6-carboxyhexyl)-2,4-dideoxy-5-C-[(1E,3S)-3-hydroxy-1-octen-1-yl]-, (5R)-

Molecular Formula:C₂₀H₃₆O₆

Molecular Weight:372.496

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:577.1±50.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.547

PSA:107.22000

Exact Mass:372.251190

LogP:2.49

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (9β,13E,15S)-9,11,15-Trihydroxythrombox-13-en-1-oic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-erythro-Pentopyranose, 4-(6-carboxyhexyl)-2,4-dideoxy-5-C-[(1E,3S)-3-hydroxy-1-octen-1-yl]-, (5R)- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,D-erythro-Pentopyranose, 4-(6-carboxyhexyl)-2,4-dideoxy-5-C-[(1E,3S)-3-hydroxy-1-octen-1-yl]-, (5R)- Use and application,(9β,13E,15S)-9,11,15-Trihydroxythrombox-13-en-1-oic acid technical grade,usp/ep/jp grade.

Related News: Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid supplier Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid vendor A system that allows Chinese citizens to enter South Korea��s Jeju Island without a visa is to be temporarily suspended. 7-[(2R,3S,4S)-4,6-dihydroxy-2-[(3S)-3-hydroxyoct-1-enyl]oxan-3-yl]heptanoic acid factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.